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Abstract 25 
Over the past decade, the health care sector has become increasingly aware of the impact of 26 
pharmaceutical emissions to the environment. Yet, it remains unclear which compounds are the most 27 
relevant to address and at what point emission control is most effective. This study presents a 28 
modelling framework to prioritize pharmaceuticals based on their relative risks for aquatic organisms, 29 
using purchase and prescription data from hospitals. The framework consists of an emission prediction 30 
module and a risk prioritization module. The emission prediction module accounts for three different 31 
routes of intake (oral, intravenous, rectal), for non-patient consumption, and for delayed at-home 32 
excretion due to relatively long half-lives or prescription durations of selected pharmaceuticals. We 33 
showcase the modelling framework with 16 pharmaceuticals administered at two Dutch academic 34 
hospitals. Predictions were validated with experimental data from passive sampling in the sewer 35 
system. With the exception of metformin, all predictions were within a factor of 10 from 36 
measurements. The risk prioritization module ranks each pharmaceutical based on its predicted 37 
relative risk for aquatic organisms. The resulting prioritization suggests that emission mitigation 38 
strategies should mainly focus on antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). 39 
 40 
Highlights 41 
- Pharmaceutical emissions were estimated from clinical purchase and prescription data 42 
- Other required input data are mostly publicly available 43 
- Predicted emissions were within factor 5 from measured emissions 44 
- Painkillers were underestimated suggesting substantial consumption of OTC drugs 45 
- Prioritization highlights risk of antibiotics and painkillers to aquatic organisms 46 
 47 
Graphical abstract 48 
 49 
 50 
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1. Introduction 51 
The presence of pharmaceuticals in surface waters can trigger adverse effects in ecosystems and 52 
humans. Antibiotic residues in the environment, for example, have been linked to increasing levels of 53 
antimicrobial resistance in bacteria, representing a potential global threat to the medical effect of 54 
commonly administered antibiotics (Duarte et al., 2018; Rizzo et al., 2013). Besides, an increasing 55 
number of publications on antidepressants suggests that behavioral changes in wildlife and aquatic 56 
species might occur at environmentally relevant concentrations (e.g., Ford and Fong, 2016). Yet, other 57 
pharmaceuticals have been reported to cause hormonal disorders in riverine fish leading to 58 
reproductive stress and hence endangering exposed populations (e.g. Tyler et al., 1998). 59 
Due to rising life expectancies, growing populations and medical advancements, the consumption of 60 
pharmaceuticals is expected to further increase in the near future (aus der Beek et al., 2016; 61 
Oldenkamp et al., 2013). After intake, most pharmaceuticals are not entirely metabolized in the human 62 
body but can partially enter the sewer system via excretion. Currently applied technologies in 63 
wastewater treatment plants (WWTPs) remove pharmaceuticals to varying extents. Consequently, 64 
pharmaceuticals that are not completely removed, are discharged with the WWTP effluent into 65 
receiving water bodies. Pharmaceutical residues have not only been found in surface waters all over 66 
the world (e.g., Archer et al., 2017; Richmond et al., 2018), but increasingly also in groundwater sources 67 
and in drinking water (e.g., aus der Beek et al., 2016; Khan and Nicell, 2015; Moermond, 2016). This 68 
calls for strategies to reduce and if possible, prevent pharmaceutical emissions to the aquatic 69 
environment.  70 
In an urban context, hospitals are often regarded as emission hotspots for pharmaceuticals (Herrmann 71 
et al., 2015; Verlicchi et al., 2014). Over the past years, the environmental awareness of hospitals has 72 
increased. Several initiatives currently promote more sustainable health care on a global scale (e.g. 73 
https://noharm.org/, http://www.healthierhospitals.org/). In the Netherlands, a new integrative 74 
strategy towards reducing pharmaceutical emissions to surface water was launched in 2016 (Dijksma, 75 
2017; https://jamdots.nl/view/239/medicijnresten-uit-water). Since then, policy makers, pharmacists, 76 
drinking water companies, water authorities and hospital managers began to collaborate more closely 77 
to reduce the load of pharmaceuticals entering the surface water. Even though not legally compulsory, 78 
many hospitals consider on-site treatment measures to reduce their pharmaceutical emissions to the 79 
environment. Yet, it remains unclear which compounds are most relevant to mitigate and at what point 80 
emission control is most effective.  81 
Measuring campaigns to assess hospital emissions are reactive, expensive and time-consuming. 82 
Instead, emission estimation models based on purchase and prescription data could represent a 83 
relatively simple method to estimate pharmaceutical emissions from hospitals (e.g. Le Corre et al., 84 
2012). In combination with risk-based prioritization, pharmaceuticals can be ranked based on the risk 85 
they pose to aquatic organisms (Chèvre et al., 2013; Escher et al., 2011; ). Compound prioritization is 86 
of crucial importance for several reasons: (1) monitoring campaigns could be fine-tuned to save costs, 87 
(2) hospital-specific shortlists of critical pharmaceuticals could be created to help identify the measures 88 
that are most effective in reducing risks, (3) hospitals can comprehensively quantify the environmental 89 
impact resulting from their pharmaceutical prescribing. 90 
This study presents a generic framework to prioritize pharmaceuticals based on their relative risks for 91 
aquatic organisms due to hospital emissions. The framework consists of an emission estimation 92 
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module and a risk prioritization module, designed to be applicable in practice. The former uses 93 
purchase and prescription data from hospitals as input data, while the latter requires data on removal 94 
efficiencies of the selected pharmaceuticals for the respective WWTP. The framework was applied to 95 
estimate the emission of 16 pharmaceuticals at two Dutch academic hospitals (Radboudumc and 96 
Utrecht UMC), and to rank these pharmaceuticals based on predicted relative risks for aquatic 97 
organisms. The emission module was tested and validated in a case study, using measurement data 98 
collected by means of passive sampling in the sewer system. 99 
 100 
2. Materials and methods 101 
2.1 Emission and prioritization framework 102 
2.1.1 Emission estimation module 103 
The aim of the emission module is to predict pharmaceutical emissions to the hospital wastewater 104 
(Equation 1). Using a mass balance approach, the total emission load of pharmaceutical x to the 105 
hospital wastewater 𝐸𝐸𝐻𝐻𝐻𝐻𝐻𝐻,𝑥𝑥 (g year-1) was assumed to originate from hospitalized patients  𝐸𝐸𝑝𝑝,𝑥𝑥  (g 106 
year-1) and staff working at the hospital  𝐸𝐸𝑛𝑛𝑝𝑝,𝑥𝑥  (g year-1).  107 
 𝐸𝐸𝐻𝐻𝐻𝐻𝐻𝐻,𝑥𝑥 =  𝐸𝐸 𝑝𝑝,𝑥𝑥 + 𝐸𝐸𝑛𝑛𝑝𝑝,𝑥𝑥        (1) 108 
 109 
The total emission load of pharmaceutical x from hospitalized patients, 𝐸𝐸𝑝𝑝,𝑥𝑥  (g year-1), (Equation 2) 110 
was then calculated by multiplying the mass of active pharmaceutical ingredient administered via 111 
intake route i (oral, intravenous, or rectal), 𝑀𝑀𝑥𝑥,𝑖𝑖 (g year-1), and the excretion fraction for that intake 112 
route 𝑓𝑓𝑒𝑒𝑥𝑥𝑒𝑒,𝑥𝑥,𝑖𝑖 (dimensionless). As some patients are discharged from the hospital before their 113 
medication is finished or excretion has been completed, the emissions by hospitalized patients were 114 
corrected for the fraction of the medication excreted at home 𝑓𝑓ℎ𝑜𝑜𝑜𝑜𝑒𝑒,𝑥𝑥,𝑖𝑖 (dimensionless): 115  𝐸𝐸𝑝𝑝,𝑥𝑥 = ∑ ((𝑖𝑖 𝑀𝑀𝑥𝑥,𝑖𝑖 ∗  𝑓𝑓𝑒𝑒𝑥𝑥𝑒𝑒,𝑥𝑥,𝑖𝑖) ∗ (1 − 𝑓𝑓ℎ𝑜𝑜𝑜𝑜𝑒𝑒,𝑥𝑥,𝑖𝑖))    (2) 116 
 117 
The fraction of the administered dose that is excreted as parent compound, 𝑓𝑓𝑒𝑒𝑥𝑥𝑒𝑒,𝑥𝑥,𝑖𝑖, was calculated for 118 
all relevant intake routes. Since broad ranges are reported in literature and online databases 119 
(PubChem, 2019; DrugBank, 2018; Zorginstituut Nederland, 2019), we used the mean of the reported 120 
fractions per compound. A combined excretion fraction was calculated by adding the partial urinary 121 
and fecal excretion fractions for each intake route (Appendix A). For most pharmaceuticals, common 122 
prescription patterns were considered as described in the summary of product characteristics that are 123 
online available from the Dutch medicines evaluation board (https://www.cbg-meb.nl/).  124 
When common prescription duration exceeds the average time of hospitalization, or when 125 
pharmaceuticals have a relatively slow body clearance, i.e. a relatively long elimination half-life (t1/2), 126 
delayed excretion might cause a substantial part of hospital prescriptions to be emitted at-home into 127 
domestic instead of hospital wastewater. Therefore, at-home excretion was determined according to 128 
the respective dosing scheme and pharmacokinetic characteristics (see Appendix B1). For 129 
pharmaceuticals administered in multiple dosing routines, 𝑓𝑓ℎ𝑜𝑜𝑜𝑜𝑒𝑒,𝑥𝑥,𝑖𝑖 was calculated using the area-130 
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under-the-curve method. For pharmaceuticals that are typically administered as single dose (e.g. 131 
contrast media), plasma concentration ratios were used (see Appendix B2). 132 
Next to at-home excretion, pharmaceutical emission loads by non-patients 𝐸𝐸 𝑛𝑛𝑝𝑝,𝑥𝑥 (g year-1) were 133 
estimated. Since both Radboudumc and Utrecht UMC are academic hospitals, the workforce consists 134 
of staff as well as students associated with the respective universities. Employment data were provided 135 
by the hospitals and expressed as full-time equivalents. Permanent staff was assumed to be aged 25-136 
65 years and to spend 40 hours weekly at their workplace, while students were assumed to be aged 137 
15-24 and to spend 32 hours weekly at the hospital. For non-patient emissions, only oral intake was 138 
included since we considered communal intravenous or rectal intake of pharmaceuticals unlikely. 139 
To calculate the emission loads by the hospital staff and students (Equation 3), publicly available 140 
national prescription data (www.gipdatabank.nl) were used. We assumed the per capita consumption 141 
by staff and students at the hospital to be represented by the national per capita consumption of their 142 
respective age groups. As such, per capita consumption by age group Ag was calculated by multiplying 143 
the national number of items issued to that age group 𝑁𝑁𝑥𝑥,𝐴𝐴𝐴𝐴,𝑁𝑁𝑁𝑁 with the mass of the active 144 
pharmaceutical ingredient (API) contained per dose 𝐷𝐷𝑥𝑥 (g), and divided by the total number of Dutch 145 
citizens in the specific age group 𝑃𝑃𝐴𝐴𝐴𝐴,𝑁𝑁𝑁𝑁. Total annual consumption volumes by staff and students 146 
working at the hospital were subsequently calculated by multiplication with their population sizes 147 
𝑆𝑆𝑃𝑃𝐴𝐴𝐴𝐴,ℎ𝑜𝑜𝑜𝑜𝑝𝑝𝑖𝑖𝑜𝑜𝑜𝑜𝑜𝑜. The resulting annual consumption by staff and students was then corrected for the time 148 
spent at the hospital 𝑓𝑓𝑜𝑜𝑖𝑖𝑜𝑜𝑒𝑒 (dimensionless), and subsequently multiplied by the previously determined 149 
excretion fraction 𝑓𝑓𝑒𝑒𝑥𝑥𝑒𝑒,𝑥𝑥,𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 for oral intake. For detailed calculations see Appendix C. 150 
𝐸𝐸 𝑛𝑛𝑝𝑝,𝑥𝑥 = ∑ �𝑁𝑁𝑥𝑥,𝐴𝐴𝐴𝐴,𝑁𝑁𝑁𝑁 ∗  𝐷𝐷𝑥𝑥  ∗ 𝑆𝑆𝑆𝑆𝐴𝐴𝐴𝐴,ℎ𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑆𝑆𝐴𝐴𝐴𝐴,𝑁𝑁𝑁𝑁 ∗ 𝑓𝑓𝑜𝑜𝑖𝑖𝑜𝑜𝑒𝑒,𝐴𝐴𝐴𝐴� ∗ 𝑓𝑓𝑒𝑒𝑥𝑥𝑒𝑒,𝑥𝑥,𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜2𝐴𝐴𝐴𝐴=1   (3) 151 
 152 
2.1.2 Risk prioritization module 153 
The aim of the risk prioritization module is to rank pharmaceuticals based on their relative risk for 154 
aquatic organisms, expressed as their risk quotients 𝑅𝑅𝑅𝑅𝑥𝑥,𝑝𝑝. Hereto, predicted emission loads (g year-155 
1) had to be converted to concentrations per pharmaceutical 𝐶𝐶𝑥𝑥 (ng L-1), since the 𝑅𝑅𝑅𝑅𝑥𝑥 is commonly 156 
defined as predicted (or measured) concentration divided by the predicted no-effect concentration of 157 
the respective pharmaceutical 𝑃𝑃𝑁𝑁𝐸𝐸𝐶𝐶𝑥𝑥 (ng L-1). To calculate 𝐶𝐶𝑥𝑥, the predicted emission loads to the 158 
respective hospital wastewater 𝐸𝐸𝐻𝐻𝐻𝐻𝐻𝐻𝑥𝑥 (g year-1) were multiplied with the fraction of each 159 
pharmaceutical that is passing the WWTP 𝑓𝑓𝑝𝑝𝑜𝑜𝑜𝑜𝑜𝑜,𝑥𝑥 (dimensionless).In our case we used hereto 1 - 160 
observed removal efficiency during the sampling campaign (see Table 1). Subsequently, a factor of 109 161 
was applied to convert the pharmaceutical load in the effluent from ng into kg. Assuming a constant 162 
daily dry weather flow 𝑅𝑅𝐷𝐷𝐻𝐻 (L day-1) for the respective WWWTP, the resulting effluent load was then 163 
divided by the annual dry weather discharge i.e. 𝑅𝑅𝐷𝐷𝐻𝐻 ∗ 365 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑  resulting in a conservative 164 
prediction  of the yearly average effluent concentration 𝐶𝐶𝑥𝑥 .  This results in Equation 4:  165  𝑅𝑅𝑅𝑅𝑥𝑥,𝑝𝑝 = 𝐶𝐶𝑥𝑥𝑆𝑆𝑁𝑁𝑃𝑃𝐶𝐶𝑥𝑥 =  𝑃𝑃𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 ∗ 𝑓𝑓𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜,𝑥𝑥 ∗ 109𝑄𝑄𝐷𝐷𝐷𝐷 ∗ 365  ∗ 𝑆𝑆𝑁𝑁𝑃𝑃𝐶𝐶𝑥𝑥         (4) 166 
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Table 1 - Observed WWTP removal efficiencies in percent during the sampling campaign in Nijmegen and Utrecht respective. 167 
If no removal percentage is reported, the compound was measured below the detection limit in both influent and effluent. 168 
Negative removal efficiencies indicate an increase of measured loads during treatment. 169 
 170 
Observed WWTP removal efficiencies 
(%) 
Compound Nijmegen Utrecht 
azithromycin -10.8 0.9 
carbamazepine -42.0 -39.5 
ciprofloxacin 96.1 91.4 
cytarabine -85.2 -1674.5 
diclofenac -43.4 -113.6 
fluoxetine -2.7 5.6 
gemfibrozil 41.5 -166.7 
ibuprofen 97.4 94.4 
ifosfamide -3.8  - 
iomeprol -64.3  - 
iopromide  -  -57.2 
metformin 90.5 99.0 
metoprolol -17.8 -21.9 
naproxen 92.3 70.0 
paracetamol 97.9 100.0 
sulfamethoxazole  -12.4 34.7 
trimethoprim 33.5 6.4 
 171 
The PNEC values for the selected pharmaceuticals were obtained according to the assessment factor 172 
(AF) method (ECHA, 2017), and based on ecotoxicity data compiled from literature (SI 3). The AF 173 
method considers the amount of available toxicity data for a certain chemical compound for different 174 
species. The more toxicity data available for a wide range of species, the lower the assigned assessment 175 
factor. For example, if only one acute LC50 or EC50 value is available for each of the basic trophic levels 176 
(represented by fish, daphnia and algae), the value for the most sensitive species is divided by an 177 
assessment factor of 1000. In contrast, if chronic no-observed effect concentration (NOEC) values are 178 
available for at least three species representing three different trophic levels, the value for the most 179 
sensitive species is divided by an assessment factor of only 10. A detailed overview of all PNECs and 180 
safety factors used can be found in Appendix D. 181 
2.1.3 Ranking strategies 182 
The final 𝑅𝑅𝑅𝑅𝑥𝑥s were ranked for prioritization. The highest-ranking compounds thus either exert the 183 
highest potential environmental harm to aquatic organisms or entail the highest uncertainty regarding 184 
the related risk due to limited ecotoxicological data (i.e. translates into a high AF). Nonetheless, 185 
mitigation strategies are desirable in both cases: emissions should be mitigated if sufficient evidence 186 
proofs its risk to the aquatic environment. On the other side, emissions should be mitigated until it is 187 
sufficiently proven that a compound does not exert a considerable risk to the aquatic environment 188 
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(precautionary principle). Therefore, the ranking indicates on which compounds mitigation strategies 189 
by hospital should focus. In total three different ranking strategies were assessed for both hospitals.  190 
The first strategy prioritizes the total emissions of a hospital into the HWW based on associated risks 191 
to the aquatic environment. Therefore, this strategy compares the predicted concentrations in HWW 192 
(Equation 1) with the measured concentrations in HWW (Equation 5). The predicted concentrations in 193 
the HWW consist of the emissions of hospitalized patients and the emissions of non-patients. Ranking 194 
1 thus assesses the environmental risks resulting from the physical boundaries of the hospital (i.e. its 195 
wastewater outlet pipes). 196 
The second strategy prioritizes emissions exclusively from hospitalized patients and thus represents 197 
the action range for a hospital for on-site measures. Hereto, the predicted concentrations 198 
corresponding to hospitalized patients (Equation 2) were compared to the measured concentrations. 199 
Since the measured concentrations also include emissions by non-patients, the measured 200 
concentrations were corrected by the relative contribution of non-patients (Equation 3). To assess the 201 
similarity of the rankings 1 and 2 between measured and predicted emissions, Spearman’s rank 202 
correlation coefficients were calculated. 203 
In a wider sense, hospitals may not only influence the emissions passing through their own HWW 204 
outlet, but also the share of emissions resulting from pharmaceuticals prescribed at hospital but 205 
consumed at home. Therefore, the third strategy prioritizes emissions by all hospital-associated 206 
patients based on related risks to the environment by comparing the predicted emissions by patients 207 
based on prescriptions (regardless if excretion occurs within the hospital or outside) to the measured 208 
emissions of hospitalized patients corrected for the relative contribution of non-patients. This last 209 
ranking indicates thus the action range by a hospital for measures on an urban scale. 210 
 211 
 212 
2.2 Case study 213 
2.2.1 Hospitals 214 
To apply and showcase the developed model, two Dutch academic hospitals were approached. 215 
Radboudumc is one of two hospitals located in the city of Nijmegen, with a population of 216 
approximately 170,000 inhabitants in 2015 (Gemeente Nijmegen, 2019). Radboudumc counts more 217 
than 10,000 employees, about 2,700 students and 626 beds (Radboudumc, 2016). Utrecht UMC is one 218 
of three hospitals in the city of Utrecht, with a population of approximately 340,000 inhabitants in 219 
2016 (Gemeente Utrecht, 2019). Utrecht UMC employs over 11,000 people, 3,700 students and counts 220 
1,042 beds (UMC Utrecht, 2017). Both hospitals provided monthly purchase data (Radboudumc: May 221 
2015; Utrecht UMC: April 2016) for the selected pharmaceuticals (Section 2.2.2), specified for oral, 222 
intravenous and rectal administration, which we extrapolated to annual consumption. In this, we 223 
assumed that pharmaceuticals purchased by a hospital are consumed within the month of purchase 224 
and exclusively by the patients of the respective hospital. We furthermore assumed both months to 225 
represent baseline months for an entire year as the purchased amounts per pharmaceutical in April 226 
and May are very close to the annual monthly means (see Appendix E). Over the counter 227 
pharmaceuticals (OTCs) were not considered, although their contribution was inevitably measured 228 
during the sampling campaign.  229 
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2.2.2 Substance selection 230 
The pharmaceuticals were chosen in close consultation with both hospitals. Each pharmaceutical 231 
selected had to meet two criteria, i.e. it had to be (1) used by both hospitals, and (2) detectable using 232 
the passive samplers to enable validation of the model results. Furthermore, a group criterion was 233 
defined, i.e. (3) the selection had to cover a wide range of pharmaceutical classes. Since both hospitals 234 
used different iodinated contrast media, criterion 1 could not be met for this group and we decided to 235 
select two different iodinated contrast media, i.e. one for each hospital. The list of pharmaceuticals 236 
assessed is shown in Table 2.  237 
Table 2 – Selection of pharmaceuticals included in case study. RUMC means Radboudumc, UUMC refers to Utrecht UMC. 238 
Therapeutic group Compound CAS number 
Antibiotics Azithromycin 117772-70-0 
 Ciprofloxacin 85721-33-1 
 Sulfamethoxazole 723-46-6 
Trimethoprim 
 
738-70-5 
Antineoplastics Cytarabine 147-94-4 
Ifosfamide 
 
3778-73-2 
Iodinated contrast media Iomeprol (RUMC) 78649-41-9 
Iopromide (UUMC) 
 
73334-07-3 
Non-steroidal anti-inflammatory drugs (NSAID) Diclofenac 15307-86-5 
Ibuprofen 15687-27-1 
Naproxen 22204-53-1 
Paracetamol 
 
103-90-2 
Anticonvulsants Carbamazepine 
 
298-46-4 
Antidepressants Fluoxetine 
 
54910-89-3 
Lipid regulators Gemfibrozil 
 
25812-30-0 
Antihyperglycemics Metformin 
 
657-24-9 
β-blockers Metoprolol 
 
37350-58-6 
 239 
2.2.3 Field measurements 240 
To validate the modelled emissions, loads of the selected pharmaceuticals were measured using 241 
passive samplers. Field measurements were conducted during the same month as indicated above for 242 
the respective hospitals, and extrapolated to annual emissions. In total 7 measuring locations were 243 
selected. Per measuring location, two adsorption samplers (Speedisk®) were placed. To calculate the 244 
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emission loads (Equations 5 and 6), we assumed an average sampling rate Rs per sampler of 50 ml day-245 
1 which is consistent with experimental tests performed by Deltares (Smedes et al., 2013; unpublished 246 
results). Furthermore, the flow rate was measured at each sampling location so that wastewater loads 247 
could be calculated (Appendix F). 248 
In Nijmegen, samplers were placed on May 20th 2015 and retrieved on June 1st 2015 covering a 249 
sampling duration of 12 days. They were placed at the two main outlets where wastewater effluent 250 
from Radboudumc enters the sewer, and at the influent and effluent points of the local WWTP. In 251 
Utrecht, samples were obtained similarly for a period of eight days from April 11th 2016 to April 19th 252 
2016. In total, three locations were chosen for sampling: at the central collection point for all hospital 253 
effluent of the Utrecht UMC, and at the influent and effluent points of the local WWTP. 254 
For transportation, the samplers were cooled and stored in glass jars. Upon arrival at the laboratory, 255 
the samples were stored in the dark at a temperature of -18° Celsius. Samplers were extracted with 256 
dichloromethane and ethanol. Extracts were dried over sodium sulphate and concentrated to a small 257 
volume. All extracts were stored in a dark environment at 1-5°C until further analysis. 258 
The analysis was performed according to an internal protocol previously described in e.g. Kivits et al.  259 
(2018). The 17 analytes and internal standards were detected by an Agilent 1260 series high-260 
performance liquid chromatographer using a 100 x 2.1 mm, 2.6 mm Kinetex column (Phenomenex, 261 
Utrecht, the Netherlands) coupled with an Agilent 6460 triple quadrupole LC/MS with Jetstream 262 
Electron Spray Ionisation (ESI) and multiple reaction monitoring (MRM). A sample volume of 5 mL was 263 
injected with a column temperature of 60 °C and a flowrate of 200 mL min-1. The sample was eluted 264 
with a gradient of 1mM ammonium fluoride with 0.01% acetic acid in Milli-Q water (eluent A)  and 265 
methanol (eluent B) and with flow rates of 0.5 mL min-1. Eluent A was increased from 5% to 90% in 10 266 
min and maintained for 3 min. After this it is decreased to 5% in 0.1 min and maintained for 1.9 min to 267 
complete the cycle of 15 min. Mass spectrometry was performed with a gas temperature of 350 °C and 268 
a flow rate of 7 L min-1. Sheath gas temperature was set at 350 °C with a flow rate of 12 L min-1. The 269 
capillary voltage was set at 3500 V. The target compounds were determined with one precursor ion 270 
and two product ions. For information about mass-to-charge ratios, retention times and ratios see SI 271 
4. Calibration was done before measuring the samples with known amounts of the analytes in 9 steps 272 
with concentrations ranging between 0 and 50 ng mL-1. The limit of detection (LOD) and limit of 273 
quantification (LOQ) of the analytes were determined with signal-to-noise ratios of 1:3 and 1:10 274 
respectively. Average recoveries and concentrations for the LOD and LOQ  are given in SI 4. The method 275 
resulted in values for LOQ ranging between 0.5 and 2.6 ng mL-1. 276 
The measured loads 𝐿𝐿𝑥𝑥 (g) on the samplers were extrapolated to annual emission loads per 277 
pharmaceutical 𝑀𝑀𝐸𝐸𝐿𝐿 𝑥𝑥 (g year-1) according to Equation 5. The load per sampler was divided by the 278 
sampling rate Rs (L day-1) and multiplied by the average discharge of the respective outlet 𝑅𝑅�𝑜𝑜𝑜𝑜𝑜𝑜 (L day-279 
1) during the sampling campaign. This resulted in the average daily emission load (g day-1), which was 280 
divided by the sampling duration 𝑇𝑇𝑜𝑜𝑜𝑜𝑜𝑜𝑝𝑝𝑜𝑜𝑖𝑖𝑛𝑛𝐴𝐴  (days). This value was multiplied by 365 days, resulting 281 
in the annual emission per pharmaceutical (g year-1). A sampling rate (Rs) of 0.05 liter day-1 was 282 
assumed for each sampler resulting in a total sampling volume of approximately one liter for each of 283 
the two case study locations. More detailed information on sampling locations and the exact 284 
calculations are provided in Appendix F.  285 
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𝑀𝑀𝐸𝐸𝐿𝐿 𝑥𝑥 =  𝑁𝑁𝑥𝑥 ∗𝑄𝑄�𝑜𝑜𝑜𝑜𝑜𝑜∗ 365𝑅𝑅𝑜𝑜∗𝑇𝑇𝑜𝑜𝑜𝑜𝑠𝑠𝑜𝑜𝑜𝑜𝑜𝑜𝑠𝑠𝐴𝐴        (5) 286 
Like discussed in 2.1.2, also the measured emission loads had to be converted into concentrations 287 
𝑀𝑀𝐸𝐸𝐶𝐶𝑥𝑥 (ng L-1) in order to perform the risk prioritization. Therefore, equation 4 was slightly adapted, 288 
by replacing 𝐸𝐸𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 with 𝑀𝑀𝐸𝐸𝐿𝐿 𝑥𝑥: 289 
𝑅𝑅𝑅𝑅𝑥𝑥,𝑜𝑜 = 𝑀𝑀𝑃𝑃𝐶𝐶𝑥𝑥𝑆𝑆𝑁𝑁𝑃𝑃𝐶𝐶𝑥𝑥 =  𝑀𝑀𝑃𝑃𝑁𝑁 𝑥𝑥 ∗ 𝑓𝑓𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜,𝑥𝑥 ∗ 109𝑄𝑄𝐷𝐷𝐷𝐷 ∗ 365  ∗ 𝑆𝑆𝑁𝑁𝑃𝑃𝐶𝐶𝑥𝑥        (6) 290 
 291 
2.2.4 Model parameterization 292 
Pharmacokinetic data were used to determine excretion fractions and the at-home excretion fractions. 293 
The required data (absorption fractions, metabolism, elimination half-lives) were retrieved from 294 
following publicly accessible online databases: 295 
• Dutch medicine evaluation board (https://www.cbg-meb.nl/) 296 
• Dutch National Health Care Institute (www.farmacotherapeutischkompas.nl/) 297 
• Drugs.com (www.drugs.com) 298 
• DrugBank (www.drugbank.ca) 299 
In case of missing or contradicting information, scientific literature was consulted. A detailed overview 300 
of the excretion fractions used and corresponding references is provided in Appendix A. The data and 301 
equations used to estimate at-home excretion can be found in Appendix B. 302 
National consumption data, expressed as the defined daily doses (DDD), were used to estimate the 303 
non-patient consumption, and were retrieved from an online database maintained by the Dutch 304 
National Health Care Institute (www.gipdatabank.nl). Data on the number of staff and students of the 305 
hospitals were retrieved from the annual reports which were issued by the hospitals and that are 306 
publicly available on their respective homepages. A detailed overview of the data used and the 307 
corresponding calculations is provided in Appendix C. 308 
Toxicological data to derive the PNEC values were retrieved from several online databases of which 309 
some are publicly accessible: 310 
• US EPA Ecotox (cfpub.epa.gov/ecotox) 311 
• Public data from REACH (echa.europa.eu)   312 
• Wikipharma (www.wikipharma.org/api_data.asp),   313 
• Dutch National Institute for Public Health and the Environment (e-TOX database, not public)   314 
• German Environment Agency (ETOX, webetox.uba.de/webETOX/index.do) 315 
• Ecotox Centre Eawag-EPFL (https://www.ecotoxcentre.ch/expert-service/quality-316 
standards/proposals-for-acute-and-chronic-quality-standards/) 317 
Data preparation for the ecotoxicological assessment was conducted according to van Vlaardingen and 318 
Verbruggen (2007). For all 16 pharmaceuticals, acute and chronic toxicity data for algae, fish and 319 
invertebrates were assessed, which are commonly used to represent the aquatic environment (ECHA, 320 
2017). Also, different endpoints (EC50, LC50, NOEC and EC10) for these species were considered. The 321 
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lowest concentration for the most sensitive species reported was subsequently divided by the 322 
corresponding assessment factor, yielding the PNECs of the respective compounds.  323 
To derive a chronic PNEC, EC10/LC10 and NOECs from chronic tests were used. ECx values where x is 324 
between 10 and 20 were divided by 2 to use them as chronic toxicity data (van Vlaardingen & 325 
Verbruggen, 2007). If the highest concentration in the test did not show any significant effect (i.e. no 326 
effect was detected) this was noted in the raw toxicity table with a greater than sign (>). These values 327 
are only included in the chronic toxicity table. If the value with the greater than sign is higher than the 328 
other available NOECs, this value was taken into account for the choice of the safety factor. EC50 and 329 
LC50 values from algae tests were used as acute values, whereas the NOEC value of the same test were 330 
considered to represent chronic values. For Daphnia magna and Ceriodaphnia dubia, it depends on 331 
the duration of the test whether values were considered acute or chronic. For both species, tests 332 
outcomes with an exposure time of 48 hours were considered acute values. Chronic values were 333 
obtained from tests with an exposure time of 21 days for D. magna and 7 days for C. dubia. Fish tests 334 
were commonly acute toxicity except for early life stage (ELS) tests. Acute L(E)C50 values were only 335 
used if sufficient chronic data was not available. A detailed description of the toxicity data, 336 
corresponding safety factors and resulting PNECs is provided in Appendix D.  337 
3. Results and discussion 338 
3.1 Predicted emission loads 339 
Table 3 presents the annual predicted emission loads for Radboudumc and Utrecht UMC.  Patients 340 
uncorrected refers to the extrapolation of clinical purchase data without correcting for at-home 341 
excretion. Hospitalized patients refers to annual emission loads corrected for at-home excretion 342 
calculated according to Equation 2, while non-patients refers to the contribution of hospital staff 343 
calculated according to Equation 3. The last column predicted HWW emissions sums the emission loads 344 
of hospitalized patients and emission loads from non-patients (Equation 1). Detailed calculations are 345 
provided in SI 1 (at-home excretion) and SI 2 (emission estimation).  346 
Table 3 - Predicted emission loads for patients, hospitalized patients, non-patients and cumulative emission loads for 347 
Radboudumc (Nijmegen) and Utrecht UMC (Utrecht).Detailed calculations are provided in SI(2). 348 
      
Radboudumc Patients, 
uncorrected 
(g/year) 
Hospitalized 
patients 
 (g/year) 
Non-patients 
(g/year) 
Predicted HWW 
emissions (g/year) 
azithromycin 894 358 145 502 
carbamazepine 54 23 175 198 
ciprofloxacin 7802 3429 318 3747 
cytarabine 306 156 0 156 
diclofenac 30 30 8 38 
fluoxetine 0 0 14 14 
gemfibrozil 104 104 55 159 
ibuprofen 430 430 438 868 
ifosfamide 216 212 0 212 
iomeprol 1258596 377579 0 377579 
iopromide 0 0 0 0 
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metformin 7392 7392 22796 30188 
metoprolol 415 415 204 619 
naproxen 774 464 428 893 
paracetamol 14533 14533 318 14851 
sulfamethoxazole  2175 538 76 614 
trimethoprim 1428 250 9 259 
     
Utrecht UMC Patients, 
uncorrected 
(g/year) 
Hospitalized 
patients 
 (g/year) 
Non-patients 
(g/year) 
Predicted HWW 
emissions (g/year) 
azithromycin 867 347 118 465 
carbamazepine 232 137 155 291 
ciprofloxacin 9291 4455 277 4732 
cytarabine 216 110 0 110 
diclofenac 36 36 7 42 
fluoxetine 3 2 12 14 
gemfibrozil 35 35 53 88 
ibuprofen 819 819 376 1195 
ifosfamide 218 218 0 218 
iomeprol 0 0 0 0 
iopromide 139201 41760 0 41760 
metformin 14204 14204 23765 37969 
metoprolol 318 318 201 519 
naproxen 222 158 422 579 
paracetamol 24172 24172 385 24557 
sulfamethoxazole  2128 695 62 758 
trimethoprim 1364 315 7 322 
 349 
3.2 Measured emission loads 350 
Table 4 presents the emission loads of the selected pharmaceuticals measured on the passive samplers 351 
after the sampling campaign of 12 days (Nijmegen) and 8 days (Utrecht) respectively. Per measuring 352 
location 2 adsorption samplers were placed, loads reported in Table 4 refer to cumulative sum of both 353 
samplers. The detection limit for all compounds is 10 ng. 354 
Table 4 – Pharmaceutical loads measured on passive samplers after the field studies in Nijmegen and Utrecht. < indicates 355 
that the measured load was below the detection limit. 356 
 Nijmegen Utrecht 
 Pit A/B Pit C 
Influent 
WWTP 
Effluent 
WWTP 
Central 
collection pit 
Influent 
WWTP 
Effluent 
WWTP 
Compound (ng) (ng) (ng) (ng) (ng) (ng) (ng) 
azithromycin 808 96 380 292 371 229 227 
carbamazepine 267 253 653 644 266 494 689 
ciprofloxacin 30282 939 995 27 827 116 10 
cytarabine 289 242 177 228 < 17 293 
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diclofenac 694 190 418 416 233 195 417 
fluoxetine < 27 25 18 < 8 8 
gemfibrozil 578 77 820 333 63 200 533 
ibuprofen 3426 3411 5022 92 2833 3798 214 
ifosfamide 1884 50 63 45 59 < < 
iomeprol 676396 227879 2185 2494 < < < 
iopromide 582 656 < < 68592 1348 2119 
metformin 318 237 656 43 403 880 8 
metoprolol 3545 1281 6008 4917 490 1194 1455 
naproxen 7343 3281 5792 311 1382 1125 338 
paracetamol 181747 46775 54654 780 37153 20726 < 
sulfamethoxazole 5201 245 338 264 451 943 616 
trimethoprim 4102 185 309 143 1098 128 120 
 357 
Table 5 presents the relative contribution of hospital emissions to the influent of the respective 358 
municipal WWTP. Although the overall contribution of both hospitals is low (<2.5% for Utrecht 359 
UMC, <1.1% for Radboudumc), some pharmaceuticals contribute above average (ciprofloxacin, 360 
trimethoprim and ifosfamide [Nijmegen]) while contrast media contribute substantially (>29% and 361 
>34% respectively). The relative contribution (%) was calculated dividing the measured loads  𝐿𝐿𝑥𝑥 362 
(g)  at the respective hospital outlet (in gram) by the measured loads at the respective WWTP inlet 363 
(SI 2) for each pharmaceutical individually as well as for the overall contribution of the hospitals 364 
(e.g. ∑ measured loads HWW / ∑ measured loads WWTP *100%).   365 
Table 5 - Relative contribution (%) of hospital emissions to the influent of the respective municipal WWTP per 366 
pharmaceutical as well as cumulatively. Pharmaceuticals that contribute above the cumulative average are indicated in 367 
bold. 368 
Compound Utrecht UMC Radboudumc 
azithromycin 1.10 0.17 
carbamazepine 0.37 0.05 
ciprofloxacin 4.86 2.28 
cytarabine - 0.21 
diclofenac 0.81 0.15 
fluoxetine 0.00 0.07 
gemfibrozil 0.22 0.06 
ibuprofen 0.51 0.1 
ifosfamide - 2.2 
iomeprol - 29.25 
iopromide 34.55 - 
metformin 0.31 0.06 
metoprolol 0.28 0.06 
naproxen 0.83 0.13 
paracetamol 1.22 0.30 
sulfamethoxazole  0.32 1.17 
trimethoprim 5.83 1.01 
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cumulative 2.47 1.09 
 369 
3.3 Comparing modelled and measured emission loads 370 
Figure 1 presents the comparison between predicted emission loads (EHWW,x) and measured emission 371 
loads (MELx) for both hospitals. The continuous line represents a EHWW,x /MELx ratio of 1, meaning that 372 
measured emission loads equal predicted emission loads. For both cases, most predicted emission 373 
loads are within a factor of 10 (dotted lines) of the measured emission loads. To assess the model 374 
performance, the median symmetric accuracy (𝝃𝝃, Xi) and the symmetric signed percentage bias (SSPB) 375 
were calculated as described in Morley et al. (2018). Metformin was in both cases significantly 376 
overestimated, while diclofenac and trimethoprim were slightly underestimated in Utrecht (Figure 1B).  377 
The hospitals use different contrast media; Radboudumc uses mainly iomeprol, while Utrecht UMC 378 
administers predominantly iopromide. Since iopromide was not purchased by Radboudumc in the 379 
selected period of time, iopromide does not appear in Figure 1A even though it was measured in low 380 
quantities (158g iopromide vs 119,618g iomeprol). Likewise, iomeprol was neither purchased nor 381 
measured at Utrecht UMC, and is therefore not depicted in Figure 1B. Furthermore, no EHWW,x/MECx 382 
ratio could be calculated for fluoxetine and cytarabine for Utrecht UMC, since these compounds were 383 
not detected in the HWW there.  384 
 385 
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 386 
 387 
Figure 1 - Difference plot of predicted and measured emissions at Radboudumc (A) and Utrecht UMC (B). The continuous line 388 
marks ideal ratio of 1 (predicted emission equals measured emission), dotted lines indicate a 10-fold deviation from it. 389 
Abbreviations stand for azithromycin (AZI), carbamazepine (CAR), ciprofloxacin (CIP), cytarabine (CYT), diclofenac (DIC), 390 
fluoxetine (FLU), gemfibrozil (GEM), ibuprofen (IBU), ifosfamide (IFO), iomeprol (IOM), iopromide (IOP), metformin (METF), 391 
metoprolol (METO), naproxen (NAP), paracetamol (PAR), sulfamethoxazole (SUL) and trimethoprim (TRI). Model performance 392 
indicators: median symmetric accuracy (𝝃𝝃), symmetric signed percentage bias (SSPB). 393 
The presented emission model based on clinical purchase data predicts hospital emissions in both 394 
cases fairly well (𝜉𝜉Nijmegen = 115%, 𝜉𝜉Utrecht = 160%) even though emissions were rather underestimated 395 
(SSPBNijmegen = -2%, SSPBUtrecht = -69%). Overall, the model performed better for Nijmegen than for 396 
Utrecht. This can be can be explained by the fact that UMC Utrecht is closely located to several other 397 
healthcare institutions, such as a military hospital and two children hospitals that appear to discharge 398 
via the same sewer pipe. Consequently, emissions from these institutions were measured but not 399 
predicted, as purchase data were only obtained from Utrecht UMC but not from the surrounding 400 
hospitals. 401 
Metformin represents a clear outlier in both cases as its emissions appear highly overestimated. 402 
Overestimation of metformin emissions was also reported in similar studies (e.g. Oosterhuis et al., 403 
2013) and could be explained by the relatively fast biodegradation to its transformation product 404 
guanylurea. This appears likely when assuming that a “competent microbial community” is well-405 
established in the sewer system (Straub, 2013; Tisler and Zwiener, 2018). In our case, however, the 406 
time from excretion in the hospital to the measured HWW outlet is rather short. Even if biodegradation 407 
proceeded very fast, this could hardly result in such a large difference between predicted and observed 408 
emission loads.  It is therefore more likely that analytical errors lead to underestimation of the emission 409 
loads, since metformin can only be determined semi-quantitatively using passive samplers (Macleod 410 
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et al., 2007; Moermond, 2016; Smedes et al., 2010). If metformin is excluded, the model performance 411 
improves slightly (𝜉𝜉Nijmegen = 105%, SSPBNijmegen = -3%; 𝜉𝜉Utrecht = 151%, SSPBUtrecht = -68%). 412 
Furthermore, in both cases diclofenac was rather underestimated suggesting a substantial 413 
consumption of OTC-diclofenac by non-patients or considerable contribution of other dosage forms. 414 
Since the present study only considers the intake of the selected pharmaceuticals, other dosage forms 415 
like dermal application of creams and gels are neglected, even though the contribution to wastewater 416 
concentrations might be significant, especially in the case of diclofenac. Letzel et al. (2009) showed, 417 
for example, that dermal application of diclofenac contributes significantly to the measured loads in 418 
wastewater as 90-95% of the API is washed-off during showering. 419 
3.4 Risk assessment and prioritization 420 
Table 6 and 7 present the results of the first and second ranking strategies for Radboudumc and 421 
Utrecht UMC, respectively. In both cases, pharmaceuticals were excluded from the ranking if either 422 
not measured or not predicted.  For Radboudumc, antibiotics score in all rankings in the top 3 based 423 
on predicted emissions. Furthermore, the first five ranking positions remain the same for both 424 
strategies. For Utrecht UMC, azithromycin and ciprofloxacin rank either 1 or 2, while diclofenac 425 
occupies rank 3 for both strategies. Ranking positions 3 to 6 remain the same for both strategies. 426 
Generally, NSAIDs score relatively high, even though the model underestimated measured loads. 427 
Likewise, selected contrast media scored along the midfield. The results suggest that mitigation 428 
strategies should especially focus on reducing the emissions of the antibiotics azithromycin, 429 
ciprofloxacin and sulfamethoxazole, as these pharmaceuticals represent the highest risk to aquatic 430 
organisms.  The method used for this ranking assigns lower PNEC values to compounds that are either 431 
more toxic or on which not much toxicity data is available. This way, both toxicity (i.e. most sensitive 432 
endpoint) and uncertainty (i.e. magnitude of AF factor) are considered.  433 
Relatively more ecotoxicity data were available for sulfamethoxazole, diclofenac and ibuprofen 434 
resulting in low application factors (i.e., of 10) while less ecotoxicity data were available and hence 435 
higher application factors (i.e., of 50-5,000) were applied for e.g. metoprolol, iomeprol or cytarabine 436 
Especially for ifosfamide very few ecotoxicity data was available resulting in the highest application 437 
factor of 10,000. For this latter group, performing additional ecotoxicity tests could result in a lower 438 
PNEC value and hence a lower estimated risk. However, performing ecotoxicity tests is often not 439 
considered as a potential risk reduction option by individual hospitals. Investing in ecotoxicity tests to 440 
optimize risk assessment could result in valuable insights that help to pinpoint priority compounds and 441 
adjust emission prevention measures accordingly.  442 
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Table 6 - Prioritization of pharmaceuticals at Radboudumc (Nijmegen) based upon predicted and measured emissions and 443 
RQs. Antibiotics are indicated in bold-print, NSAIDs in italic-print. The darker the background color, the better the ranks of 444 
predicted and measured concentrations coincide. In ranking 2, fluoxetine is not listed as neither predicted nor measured after 445 
correction for non-patient consumption.  446 
Ranking 1: Total emissions of Radboudumc into HWW 
pharmaceutical predicted RQ x,p  
(PEC/PNEC) 
measured RQ x,m    
(PEC/PNEC) 
Assessment 
factor 
azithromycin 1 3.30E-01 3 8.00E-02 50 
ciprofloxacin 2 8.54E-02 2 9.67E-02 50 
sulfamethoxazole  3 6.11E-02 4 7.34E-02 10 
diclofenac 4 5.66E-02 1 1.76E-01 10 
iomeprol 5 3.68E-02 7 1.16E-02 5000 
ibuprofen 6 1.19E-02 6 1.20E-02 10 
paracetamol 7 7.97E-03 5 1.63E-02 50 
carbamazepine 8 5.86E-03 11 1.98E-03 10 
metoprolol 9 5.02E-03 8 5.16E-03 1000 
gemfibrozil 10 3.11E-03 12 1.72E-03 50 
naproxen 11 2.12E-03 10 3.32E-03 50 
trimethoprim 12 1.76E-03 9 3.96E-03 1000 
fluoxetine 13 1.75E-03 13 4.04E-04 50 
cytarabine 14 8.88E-04 14 3.90E-04 3000 
metformin 15 1.49E-04 16 3.55E-07 10 
ifosfamide 16 1.42E-05 15 1.76E-05 10000 
Spearman's rho: 0.929     
 447 
Ranking 2: Action range for on-site measures by Radboudumc  
pharmaceutical predicted RQ x,p   
(PEC/PNEC) 
measured RQ x,m  
(PEC/PNEC) 
Assessment 
factor 
azithromycin 1 2.35E-01 4 5.69E-02 50 
ciprofloxacin 2 7.82E-02 2 8.84E-02 50 
sulfamethoxazole  3 5.35E-02 3 6.43E-02 10 
diclofenac 4 4.53E-02 1 1.41E-01 10 
iomeprol 5 3.68E-02 6 1.16E-02 5000 
paracetamol 6 7.79E-03 5 1.60E-02 50 
ibuprofen 7 5.90E-03 7 5.96E-03 10 
metoprolol 8 3.36E-03 9 3.46E-03 1000 
gemfibrozil 9 2.03E-03 11 1.12E-03 50 
trimethoprim 10 1.70E-03 8 3.82E-03 1000 
naproxen 11 1.10E-03 10 1.73E-03 50 
cytarabine 12 8.88E-04 12 3.90E-04 3000 
carbamazepine 13 6.69E-04 13 2.26E-04 10 
metformin 14 3.66E-05 15 8.70E-08 10 
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ifosfamide 15 1.42E-05 14 1.76E-05 10000 
Spearman's rho: 0.943     
 448 
Table 7 - Prioritization of pharmaceuticals at Utrecht UMC based upon predicted and measured emissions and RQs. Antibiotics 449 
are indicated in bold-print, NSAIDs in italic-print. The darker the background color, the better the ranks of predicted and 450 
measured concentrations coincide. Cytarabine, fluoxetine, iomeprol and paracetamol are not listed as either not measured or 451 
entirely removed in WWTP.  452 
Ranking 1: Total emissions of Utrecht UMC into HWW  
pharmaceutical predicted RQ x,p    
(PEC/PNEC) 
measured RQ x,m 
(PEC/PNEC) 
Assessment 
factor 
azithromycin 1 3.26E-01 2 4.32E-01 50 
ciprofloxacin 2 2.83E-01 4 8.21E-02 50 
diclofenac 3 1.13E-01 1 1.03E+00 10 
sulfamethoxazole  4 5.22E-02 5 5.16E-02 10 
ibuprofen 5 4.19E-02 3 1.65E-01 10 
carbamazepine 6 1.01E-02 8 1.54E-02 10 
gemfibrozil 7 9.35E-03 9 1.12E-02 50 
naproxen 8 6.37E-03 6 2.52E-02 50 
metoprolol 9 5.19E-03 10 8.13E-03 1000 
trimethoprim 10 3.68E-03 7 2.08E-02 1000 
iopromide 11 4.09E-04 11 1.11E-03 100 
metformin 12 2.26E-05 13 3.99E-07 10 
ifosfamide 13 1.68E-05 12 7.53E-06 10000 
Spearman's rho: 0.896     
 453 
Ranking 2: Action range for on-site measures by Utrecht UMC  
pharmaceutical predicted RQ x,p   
(PEC/PNEC) 
measured RQ x,m   
(PEC/PNEC) 
Assessment 
factor 
ciprofloxacin 1 2.66E-01 4 7.73E-02 50 
azithromycin 2 2.43E-01 2 3.22E-01 50 
diclofenac 3 9.51E-02 1 8.66E-01 10 
sulfamethoxazole  4 4.79E-02 5 4.74E-02 10 
ibuprofen 5 2.87E-02 3 1.13E-01 10 
carbamazepine 6 4.75E-03 7 7.21E-03 10 
gemfibrozil 7 3.68E-03 10 4.40E-03 50 
trimethoprim 8 3.60E-03 6 2.04E-02 1000 
metoprolol 9 3.18E-03 9 4.98E-03 1000 
naproxen 10 1.73E-03 8 6.87E-03 50 
iopromide 11 4.09E-04 11 1.11E-03 100 
ifosfamide 12 1.68E-05 12 7.53E-06 10000 
metformin 13 8.47E-06 13 1.49E-07 10 
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Spearman's rho: 0.901     
 454 
 455 
 456 
To assess the similarity of the rankings, the Spearman’s rank correlation coefficient was determined 457 
for all four rankings. The coefficients are 0.929 (ranking 1) and 0.943 (ranking 2) for Radboudumc, and 458 
0.898 (ranking 1) and 0.901 (ranking 2) for Utrecht UMC suggesting a strong positive correlation. 459 
Overall, this suggests that prioritization based upon clinical purchase and prescription data is a viable 460 
instrument for hospitals to assess their environmental impact.  461 
Table 8 presents the outcome of the third ranking strategy for Radboudumc (above) and Utrecht UMC 462 
(below). Like in the previous rankings, the antibiotics azithromycin, sulfamethoxazole and ciprofloxacin 463 
score the highest, followed by iomeprol (Radboudumc) and diclofenac (Utrecht UMC) while other 464 
NSAIDs score along the midfield. Especially the case of trimethoprim (position 6 in Table 5 instead of 465 
position 10 and 11 in Table 3 and 4) highlights the relatively high risk that antibiotics pose to the aquatic 466 
environment. The results of ranking 3 confirm therefore that, also on an urban scale, a reduction of 467 
antibiotic emissions would be prioritized to protect aquatic ecosystems.  468 
This means that the implementation of possible measures by hospitals to protect the aquatic 469 
environment should primarily focus on these compounds, while not neglecting solutions to reduce the 470 
emissions of other compounds when those would be easy to implement. For this ranking, no 471 
Spearman’s rank correlation coefficient was determined since the ranking compares only predicted 472 
emissions. 473 
  474 
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Table 8 - Comparison of the prioritization of pharmaceuticals based on the urban impact of both hospitals. Antibiotics are 475 
indicated in bold-print, NSAIDs in italic-print. The darker the background color, the better coincide the ranks between predicted 476 
and measured concentrations. 477 
Ranking 3: Action range for measures on urban scale by Radboudumc 
pharmaceutical prescriptions RQ  
(PEC/PNEC) 
hospitalized 
patients 
RQ    
(PEC/PNEC) 
Assessment 
factor 
azithromycin 1 5.88E-01 4 5.69E-02 50 
sulfamethoxazole  2 2.16E-01 3 6.43E-02 10 
ciprofloxacin 3 1.78E-01 2 8.84E-02 50 
iomeprol 4 1.23E-01 6 1.16E-02 5000 
diclofenac 5 4.53E-02 1 1.41E-01 10 
trimethoprim 6 9.72E-03 8 3.82E-03 1000 
paracetamol 7 7.79E-03 5 1.60E-02 50 
ibuprofen 8 5.90E-03 7 5.96E-03 10 
metoprolol 9 3.36E-03 9 3.46E-03 1000 
gemfibrozil 10 2.03E-03 11 1.12E-03 50 
naproxen 11 1.84E-03 10 1.73E-03 50 
cytarabine 12 1.74E-03 12 3.90E-04 3000 
carbamazepine 13 1.59E-03 13 2.26E-04 10 
metformin 14 3.66E-05 15 8.70E-08 10 
ifosfamide 15 1.45E-05 14 1.76E-05 10000 
Ranking 3: Action range for measures on urban scale by Utrecht UMC 
pharmaceutical prescriptions RQ    
(PEC/PNEC) 
hospitalized 
patients 
RQ    
(PEC/PNEC) 
Assessment 
factor 
azithromycin 1 6.07E-01 2 3.22E-01 50 
ciprofloxacin 2 5.55E-01 4 7.73E-02 50 
sulfamethoxazole  3 1.47E-01 5 4.74E-02 10 
diclofenac 4 9.51E-02 1 8.66E-01 10 
ibuprofen 5 2.87E-02 3 1.13E-01 10 
trimethoprim 6 1.56E-02 6 2.04E-02 1000 
carbamazepine 7 8.05E-03 7 7.21E-03 10 
gemfibrozil 8 3.68E-03 10 4.40E-03 50 
metoprolol 9 3.18E-03 9 4.98E-03 1000 
naproxen 10 2.44E-03 8 6.87E-03 50 
iopromide 11 1.36E-03 11 1.11E-03 100 
ifosfamide 12 1.68E-05 12 7.53E-06 10000 
metformin 13 8.47E-06 13 1.49E-07 10 
 478 
3.5 Model applicability 479 
The presented emission estimation model and prioritization framework should be suitable to provide 480 
hospitals with sufficient exploratory information to prioritize potential emission reduction measures. 481 
21 
 
Both modules of the presented framework require a limited amount of relatively simple input data. To 482 
extrapolate from expected loads of pharmaceuticals to concentrations, data on the flow rate of the 483 
HWW effluent are required. The prioritization module requires data on removal efficiencies per 484 
pharmaceutical as well as PNEC values. If no real-time measuring data for the specific WWTP is 485 
available, average removal efficiencies reported in literature can be used. The latter, however, might 486 
compromise the accuracy of the predictions. A screening-level but comprehensive overview of the 487 
pharmaceutical emissions of a hospital can still be provided. The most limiting factor regarding the 488 
model applicability is likely the derivation of the PNEC values due to the lack of ecotoxicity data. Many 489 
substances, especially substances on the market before 2006 (so-called legacy substances) have very 490 
limited or no ecotoxicity data at all. Furthermore, selecting and assessing the quality of these 491 
ecotoxicity tests requires basic knowledge on environmental risk assessment. Besides, cleaning of 492 
collected ecotoxicity data remains a tedious and time-consuming task.  493 
3.6 Limitations 494 
3.6.1 Emission estimation model 495 
Regarding the emission model, three main limitations come to the fore. Firstly, this study considers 496 
only excretion of the parent compounds but ignores formation and effects of metabolites. After intake 497 
of a pharmaceutical, part of the API is metabolized by the human body. During this process, several 498 
metabolites can be formed in differing quantities. Depending on the specific half-life of the compound, 499 
the entire intake dose is ultimately excreted; partially as metabolites and partially as parent compound 500 
mostly via urine and feces.  501 
As the formation of metabolites is highly variable and subject to complex chemical reactions, many 502 
differing estimates are reported in literature. Furthermore, conflicting statements exist on the 503 
contribution of metabolites to the environmental risk. Some studies argue aquatic toxicity of most 504 
metabolites is lower as compared to the respective parent compound (e.g. Escher et al., 2011) while 505 
other studies report a greater toxicity for metabolites than for parent compounds (e.g. Schulze et al., 506 
2010). Consequently, assessing the formation and effects of metabolites was considered beyond the 507 
scope of the present study. This implies that the risk assessment module likely underestimates the 508 
total risk originating from a parent compound, as the toxic contribution by its metabolites is neglected 509 
leading to a non-conservative environmental risk assessment. More research is recommended to bring 510 
more clarity to this ongoing academic debate. 511 
Secondly,the emission estimation model does not account for in-sewer transformation and 512 
degradation processes that might affect the compounds (both parent compound as well as 513 
metabolites). This could potentially lead to an overestimation of pharmaceutical concentrations and 514 
thus to a conservative emission estimation. However, several studies suggest that the effect of in-515 
sewer processes on pharmaceuticals is limited mainly due to the rather short retention time in the 516 
sewer system (e.g. Jelic et al., 2014; O’Brien et al., 2017). 517 
Thirdly, the non-patients’ emissions estimated in the present study only include staff and working 518 
students, but not visitors. Visitors of hospitalized patients might contribute substantially to non-patient 519 
emissions even though spending only short periods of time at the hospital as compared to working 520 
staff. To the best of our knowledge, no data on annual numbers of visitors or average visit durations 521 
are recorded for any of the selected hospitals. Furthermore, due to the lack of data on OTCs sales or 522 
consumption, non-patient emissions are based solely on national prescription data.  523 
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3.6.2 Environmental risk assessment 524 
In this study, only 16 pharmaceuticals were considered out of more than 1300 pharmaceutical 525 
products for human use which are registered within the EU (European Commission, 2019). It is 526 
admittedly questionable how representative a ranking on such a small sample size is. Therefore, we 527 
would like to mention explicitly that the presented ranking is relative to the present compound 528 
selection. Including more or other compounds could have resulted in distinct ranking positions for the 529 
single compounds. However, we demonstrated that the method functions well and therefore we do 530 
not expect major issues when upscaling the presented framework to a larger sample size. Moreover, 531 
even though the sample size was small, some general tendencies became apparent, for example, that 532 
antibiotics represent a higher aquatic risk than other groups of pharmaceuticals. This underlines the 533 
importance of reducing antibiotic emissions to the environment.  534 
One general drawback of current risk assessment is that it does not account for potential mixture 535 
toxicity. There is general agreement that mixtures might be more toxic than the summed effects of 536 
each of the components, with aggregated responses being potentially slightly modified by synergistic 537 
processes (Kortenkamp et al., 2009). Furthermore,  the long-term effects of chronic exposure of 538 
aquatic organisms to pharmaceuticals are still largely unknown. A recent study published by Richmond 539 
et al. (2018) suggests that some pharmaceutical residues can accumulate in benthic insects and 540 
biomagnify along the food web. A growing body of literature attributes behavioral changes as well as 541 
reproductive alterations resulting from long-term exposure to low concentrations of micro pollutants 542 
including pharmaceuticals (Ford and Fong, 2016; Tyler et al., 1998). However, current risk assessments 543 
do not yet account for these behavioral changes and reproductive effects. 544 
3.6.3 Model reliability 545 
As with all kinds of predictions or models, the present one is also subject to a certain degree of 546 
uncertainty. In our case, three main sources contribute to the overall uncertainty. Firstly, an important 547 
source of uncertainty is the estimation of excretion factors used to predict pharmaceutical emissions 548 
to HWW. Excretion factors reported in literature and online databases fall within a relatively wide 549 
range suggesting large variability in pharmaceutical excretion from person to person depending on 550 
several factors like age, diet, disease and combined intake of pharmaceuticals. The uncertainty 551 
regarding excretion factors is pharmaceutical-specific: while for some pharmaceuticals (e.g. contrast 552 
media) excretion factors are around 90%, for other pharmaceuticals (e.g. diclofenac, metoprolol, 553 
ibuprofen) merely 1% of the intake is excreted. Deviations in low excretion factors will have a much 554 
larger impact on emission estimates than deviations in high excretion factors. If 2% of the ibuprofen 555 
intake was excreted instead of 1% the emission estimation of ibuprofen would double, whereas an 556 
excretion factor of 91% instead of 90% for iomeprol would carry much less weight for the emission 557 
estimation. Likewise, uncertainty around half-life data affects the emission estimation for at-home 558 
excretion.  559 
Secondly, regarding the conducted risk assessment, substantial uncertainty originates from the 560 
assessment factors applied which range from 10-10,000 depending on the number of ecotoxicological 561 
data available. In case of low data availability, PNECs might overestimate the risk of a pharmaceutical 562 
because of the high assessment factor. In case of high data availability (thus many different species 563 
tested), a low assessment factor is applied. In this case, however, there is still a risk that another 564 
species, which was not considered in the effect assessment, might be substantially more sensitive than 565 
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the least sensitive species considered. This has also implications for the prioritization, where the 566 
position of a pharmaceutical in the ranking depends on two estimated variables, i.e. the predicted 567 
environmental concentration (PEC) and the predicted no-effect concentration (PNEC), which are both 568 
subject to uncertainty. As described previously, our predicted concentrations hardly deviate more than 569 
a factor of 10 from measured concentrations. The derivation of PNECs, however, is much more 570 
uncertain. The PNEC of diclofenac, for example, can differ by a factor of 2000 depending on the 571 
endpoints chosen. If histopathological changes in fish are considered a population-relevant endpoint 572 
as suggested by Schwaiger et al. (2004) and Triebskorn et al. (2007), a much lower (conservative) PNEC 573 
of 5*10-5 mg/L is derived leading to a relatively high position for diclofenac in the ranking. If these 574 
studies are ignored because of variations in experimental setup or differing diagnostic interpretations 575 
of ecotoxicity test data (Wolf et al., 2014), a much higher (less conservative) PNEC of 0.1 mg/L is 576 
derived. Consequently, diclofenac would have scored position 16 instead of position 1 in ranking 1 577 
(Tabel 6, right column). In this study, we used the more conservative PNEC value. 578 
4. Conclusions 579 
This study demonstrated that prioritization based upon clinical purchase and prescription data is a 580 
viable instrument for hospitals to assess their environmental impact. Expensive and laborious 581 
measuring campaigns might thus not always be necessary to decide at what point mitigation measures 582 
could be most effective.  583 
The presented emission estimation model predicts pharmaceutical emissions from hospitals fairly 584 
accurately. Predicted emissions deviate mostly within a factor of 10 from measured emissions. NSAIDs 585 
are generally underestimated which is probably caused by the consumption of over the counter drugs 586 
by non-patients which was not included in our emission model.  587 
Results from prioritizing pharmaceuticals indicate that azithromycin and ciprofloxacin represent the 588 
highest risk to aquatic organisms in relation to the substance selection of this study. Similarly, non-589 
steroidal anti-inflammatory drugs (NSAIDs) scored relatively high even though the emission of this 590 
pharmaceutical group is underestimated in both cases. Emission mitigation strategies by hospitals 591 
could therefore focus their efforts primarily on reducing antibiotic and NSAID emissions.  592 
Both modules of the presented framework require a limited amount of relatively simple input data. 593 
Therefore, this study provides health care managers with a useful and pragmatic tool to acquire 594 
sufficient exploratory information on hospital emissions for prioritizing potential emission reduction 595 
measures.  596 
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(Appendix) – Describing methods and calculations to determine excretion fractions, half-lives and at-609 
home excretion, non-patient emissions, PNECs, and data on field measurements. 610 
(SI 1) - Excel presenting calculations on pharmaceutical half-lives and at-home excretion. 611 
(SI 2) - Excel presenting calculations on emission estimation and prioritization. 612 
(SI 3) – Excel presenting overview of ecotoxicological data used to derive PNECs. 613 
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